Department of Chronic Disease Prevention, Public Health Genomics Research Unit, National Institute for Health and Welfare, and Institute for Molecular Medicine Finland (FIMM), 00290 Helsinki, Finland.
Department of Chronic Disease Prevention, Public Health Genomics Research Unit, National Institute for Health and Welfare, and Institute for Molecular Medicine Finland (FIMM), 00290 Helsinki, Finland.
J Biol Chem. 2011 Nov 4;286(44):38211-38219. doi: 10.1074/jbc.M111.249482. Epub 2011 Sep 6.
Apolipoprotein A-I (apoA-I), the main protein component of high density lipoprotein (HDL), is well recognized for its antiatherogenic, antioxidant, and antiinflammatory properties. Here, we report a novel role for apoA-I as a host defense molecule that contributes to the complement-mediated killing of an important gastrointestinal pathogen, Gram-negative bacterium Yersinia enterocolitica. We specifically show that the C-terminal domain of apoA-I is the effector site providing the bactericidal activity. Although the presence of the lipopolysaccharide O-antigen on the bacterial surface is absolutely required for apoA-I to kill the bacteria, apoA-I does not interact with the bacteria directly. To the contrary, exposure of the bacteria by serum proteins triggers apoA-I deposition on the bacterial surface. As our data show that both purified lipid-free and HDL-associated apoA-I displays anti-bacterial potential, apoA-I mimetic peptides may be a promising therapeutic agent for the treatment of certain Gram-negative infections.
载脂蛋白 A-I(apoA-I)是高密度脂蛋白(HDL)的主要蛋白成分,其具有抗动脉粥样硬化、抗氧化和抗炎作用,这一点已得到广泛认可。在这里,我们报告了 apoA-I 的一个新作用,即作为宿主防御分子,有助于补体介导的杀伤一种重要的胃肠道病原体——革兰氏阴性菌肠侵袭性大肠杆菌。我们特别表明,apoA-I 的 C 末端结构域是提供杀菌活性的效应部位。尽管细菌表面的脂多糖 O-抗原的存在对于 apoA-I 杀死细菌是绝对必需的,但 apoA-I 并不与细菌直接相互作用。相反,血清蛋白暴露细菌会触发 apoA-I 在细菌表面的沉积。我们的数据表明,纯化的无脂和与 HDL 结合的 apoA-I 均具有抗细菌潜能,因此 apoA-I 模拟肽可能是治疗某些革兰氏阴性感染的有前途的治疗剂。